The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Biology Consortium, 2017Consequences of LRRK2 Rab Phosphorylation in Neurons and Astrocytes
Study Rationale:
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are important contributors to LRRK2-linked Parkinson's disease (PD); therefore, LRRK2 is an important drug target. The goal... -
Research Grant, 2017Validation of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) for Parkinson's Disease
Study Rationale:
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease... -
Research Grant, 2017A Proof-of-Concept Study of Mitochondrial Drugs in Pre-Clinical Models of Parkinson’s Disease
Study Rationale:
Mitochondrial dysfunction (powerhouse of the cell), free-radical induced injury (highly reactive atoms that can be harmful) and inflammatory mechanisms have been proposed to play a... -
Research Grant, 2017From Nose to Diagnostics: Development of an Accessible Screening Platform for Early Diagnosis of Parkinson's Disease
Study Rationale:
The aim of this study is to determine if chemicals found on the skin of those with Parkinson's disease (PD) can be used as a way to diagnose PD before motor symptoms develop. We have... -
Research Grant, 2017Development of a Clinical Flow Cytometry Assay for Accurate and Selective Measurement of GBA1 Activity in Peripheral Blood Mononuclear Cells
Study Rationale:
A protein in the brain known as glucocerebrosidase may not work properly in those with Parkinson's disease (PD). Methods currently used to monitor the activity of this protein within... -
LRRK2 Therapeutic and Safety Initiative, 2017The Effects of a LRRK2 Inhibitor on Alpha-synuclein-induced Dopamine Deficits in a Pre-clinical Model of Parkinson's Disease
Study Rationale:
In a previous study, we demonstrated that PFE360, an LRRK2 inhibitor, has neuroprotective benefits. However, several questions remain unanswered as follows: (1) Did the vehicle...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.